Glucomannan is a promising isoniazid's enhancer that inducing macrophage phagocytosis.

Autor:	Novita BD; Department of Pharmacology and Therapy, Faculty of Medicine, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia., Wasiyastuti W; Department of Physiology, Faculty of Medicine, Gadjah Mada University, Yogyakarta, Indonesia., Tjahjono Y; Department of Biomedicine, Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia., Wijaya H; Department of Biomedicine, Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia., Hadinugroho W; Department of Biomedicine, Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia., Wijaya S; Department of Biomedicine, Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia., Soegianto L; Department of Biomedicine, Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia., Theodora I; Department of Pathology, Faculty of Medicine, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia., Widoretno ETW; Department of Internal Medicine, Faculty of Medicine, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia., Samsudin K; Department of Internal Medicine, Faculty of Medicine, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia., Julian A; Department of Internal Medicine, Faculty of Medicine, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia.
Jazyk:	angličtina
Zdroj:	Journal of advanced pharmaceutical technology & research [J Adv Pharm Technol Res] 2024 Jul-Sep; Vol. 15 (3), pp. 237-241. Date of Electronic Publication: 2024 Jul 22.
DOI:	10.4103/japtr.japtr_96_24
Abstrakt:	Isoniazid (INH) is a frontline antituberculosis agent effective against Mycobacterium tuberculosis (Mtb), but the increasing challenge of avoiding multidrug-resistant tuberculosis, including INH resistance, necessitates innovative approaches. This study focused on enhancing macrophage phagocytosis to overcome INH resistance. Glucomannan, an immunomodulatory polysaccharide, emerged as a potential macrophage activator. Our objective was to characterize the glucomannan-INH mixture and assess its impact on INH efficacy and macrophage activity. Detailed examination of the glucomannan from Amorphophallus muelleri (0.05%-0.2%) was performed in several methods. INH sensitivity tests were carried out with the Mtb strain H37RV on Löwenstein-Jensen medium. Murine macrophage (RAW264.7) viability and activity were evaluated through MTT and latex bead phagocytosis assays. Ultraviolet-wavelength spectrophotometry was used to analyze chemical structure changes. Glucomannan (0.05%-0.2%) significantly enhanced murine macrophage viability and activity. When glucomannan was combined with INH, the IC50 value was greater compared to INH only. Phagocytosis assays revealed heightened macrophage activity in the presence of 0.05% and 0.1% glucomannan. Importantly, glucomannan did not compromise INH efficacy or alter its chemical structure. This study underscores the potential of glucomannan, particularly with a lower molecular weight, as a promising enhancer of INH, boosting macrophage phagocytosis against INH-resistant Mtb. These findings challenge the assumptions about the impact of glucomannan on drug absorption and prompt potential reevaluation. While specific receptors for glucomannan in macrophage phagocytosis require further exploration, the complement receptors are proposed to be potential mediators. Competing Interests: There are no conflicts of interest. (Copyright: © 2024 Journal of Advanced Pharmaceutical Technology & Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu